Dr Al G. Dossetter gained his Ph.D. from Nottingham University and after postdoctoral research at Harvard University joined AstraZeneca. He has 13 years of experience in medicinal chemistry spread across oncology (hormonal and kinase inhibitors), inflammation (OA and RA, enzyme inhibitors, and GPCR targets), and diabetes (obesity, GPCR, and enzyme inhibitors). In 2012, he cofounded MedChemica Limited to use matched molecular pair analysis to accelerate medicinal chemistry. The bulk of Al’s time is writing new software, on sales trips and working on consultancy projects. He has contributed to some of the 9 candidate drugs MedChemica has help develop with clients. Al is an enthusiastic advocate for science and is currently Chairman of the Society of Chemical Industry (SCI) Fine Chemical Group (FCG). In this role he helps organise conferences some 26 conferences every two yeats in the fields of Drug Design, Agrochemicals and Organic Synthesis.
